Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative Activity

Background: The increasing prevalence of drug resistance in cancer therapy underscores the urgent need for novel therapeutic approaches. Dual enzyme inhibitors, targeting critical kinases such as CDK2 and TRKA, represent a promising strategy. The goal of this investigation was to design, synthesize,...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed H. Attia, Deena S. Lasheen, Nermin Samir, Azza T. Taher, Hatem A. Abdel-Aziz, Dalal A. Abou El Ella
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/17/12/1667
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850239537174806528
author Mohamed H. Attia
Deena S. Lasheen
Nermin Samir
Azza T. Taher
Hatem A. Abdel-Aziz
Dalal A. Abou El Ella
author_facet Mohamed H. Attia
Deena S. Lasheen
Nermin Samir
Azza T. Taher
Hatem A. Abdel-Aziz
Dalal A. Abou El Ella
author_sort Mohamed H. Attia
collection DOAJ
description Background: The increasing prevalence of drug resistance in cancer therapy underscores the urgent need for novel therapeutic approaches. Dual enzyme inhibitors, targeting critical kinases such as CDK2 and TRKA, represent a promising strategy. The goal of this investigation was to design, synthesize, and evaluate a set of pyrazolo[1,5-<i>a</i>]pyrimidine derivatives for their dual inhibition potential toward CDK2 and TRKA kinases, along with their potential antiproliferative against cancer cell lines. Methods: A set of pyrazolo[1,5-<i>a</i>]pyrimidine derivatives (<b>6a</b>–<b>t</b>, <b>11a</b>–<b>g</b>, and <b>12</b>) was synthesized and subjected to in vitro enzymatic assays to determine their inhibitory activity against CDK2 and TRKA kinases. Selected compounds were further assessed for antiproliferative effects across the set of 60 cell lines from the NCI, representing various human cancer types. Additionally, simulations of molecular docking were conducted to explore the modes of binding for the whole active compounds and compare them with known inhibitors. Results: Compounds <b>6t</b> and <b>6s</b> exhibited potent dual inhibitory activity, showing an IC<sub>50</sub> = 0.09 µM and 0.23 µM against CDK2, and 0.45 µM against TRKA, respectively. These results were comparable to reference inhibitors ribociclib (CDK2, IC<sub>50</sub> = 0.07 µM) and larotrectinib (TRKA, IC<sub>50</sub> = 0.07 µM). Among the studied derivatives, compound <b>6n</b> displayed a notable broad-spectrum anticancer activity, achieving a mean growth inhibition (GI%) of 43.9% across 56 cell lines. Molecular docking simulations revealed that the synthesized compounds adopt modes of binding similar to those of the lead inhibitors. Conclusions<b>:</b> In this study, prepared pyrazolo[1,5-<i>a</i>]pyrimidine derivatives demonstrated significant potential as dual CDK2/TRKA inhibitors, and showed potent anticancer activity toward diverse cancer cell lines. These findings highlight their potential as key compounds for the design of novel anticancer therapeutics.
format Article
id doaj-art-5bb2f8142bc140b2bfc8fd6413c1c340
institution OA Journals
issn 1424-8247
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Pharmaceuticals
spelling doaj-art-5bb2f8142bc140b2bfc8fd6413c1c3402025-08-20T02:01:09ZengMDPI AGPharmaceuticals1424-82472024-12-011712166710.3390/ph17121667Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative ActivityMohamed H. Attia0Deena S. Lasheen1Nermin Samir2Azza T. Taher3Hatem A. Abdel-Aziz4Dalal A. Abou El Ella5Department of Pharmaceutical Chemistry, Faculty of Pharmacy, October 6 University (O6U), Giza 12585, EgyptPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, EgyptPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, EgyptDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, EgyptDepartment of Applied Organic Chemistry, National Research Center, Cairo 12622, EgyptPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, EgyptBackground: The increasing prevalence of drug resistance in cancer therapy underscores the urgent need for novel therapeutic approaches. Dual enzyme inhibitors, targeting critical kinases such as CDK2 and TRKA, represent a promising strategy. The goal of this investigation was to design, synthesize, and evaluate a set of pyrazolo[1,5-<i>a</i>]pyrimidine derivatives for their dual inhibition potential toward CDK2 and TRKA kinases, along with their potential antiproliferative against cancer cell lines. Methods: A set of pyrazolo[1,5-<i>a</i>]pyrimidine derivatives (<b>6a</b>–<b>t</b>, <b>11a</b>–<b>g</b>, and <b>12</b>) was synthesized and subjected to in vitro enzymatic assays to determine their inhibitory activity against CDK2 and TRKA kinases. Selected compounds were further assessed for antiproliferative effects across the set of 60 cell lines from the NCI, representing various human cancer types. Additionally, simulations of molecular docking were conducted to explore the modes of binding for the whole active compounds and compare them with known inhibitors. Results: Compounds <b>6t</b> and <b>6s</b> exhibited potent dual inhibitory activity, showing an IC<sub>50</sub> = 0.09 µM and 0.23 µM against CDK2, and 0.45 µM against TRKA, respectively. These results were comparable to reference inhibitors ribociclib (CDK2, IC<sub>50</sub> = 0.07 µM) and larotrectinib (TRKA, IC<sub>50</sub> = 0.07 µM). Among the studied derivatives, compound <b>6n</b> displayed a notable broad-spectrum anticancer activity, achieving a mean growth inhibition (GI%) of 43.9% across 56 cell lines. Molecular docking simulations revealed that the synthesized compounds adopt modes of binding similar to those of the lead inhibitors. Conclusions<b>:</b> In this study, prepared pyrazolo[1,5-<i>a</i>]pyrimidine derivatives demonstrated significant potential as dual CDK2/TRKA inhibitors, and showed potent anticancer activity toward diverse cancer cell lines. These findings highlight their potential as key compounds for the design of novel anticancer therapeutics.https://www.mdpi.com/1424-8247/17/12/1667synthesispyrazolo[1,5-<i>a</i>]pyrimidineanticancer activityTRKACDK2
spellingShingle Mohamed H. Attia
Deena S. Lasheen
Nermin Samir
Azza T. Taher
Hatem A. Abdel-Aziz
Dalal A. Abou El Ella
Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative Activity
Pharmaceuticals
synthesis
pyrazolo[1,5-<i>a</i>]pyrimidine
anticancer activity
TRKA
CDK2
title Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative Activity
title_full Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative Activity
title_fullStr Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative Activity
title_full_unstemmed Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative Activity
title_short Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative Activity
title_sort design synthesis and molecular modeling of pyrazolo 1 5 i a i pyrimidine derivatives as dual inhibitors of cdk2 and trka kinases with antiproliferative activity
topic synthesis
pyrazolo[1,5-<i>a</i>]pyrimidine
anticancer activity
TRKA
CDK2
url https://www.mdpi.com/1424-8247/17/12/1667
work_keys_str_mv AT mohamedhattia designsynthesisandmolecularmodelingofpyrazolo15iaipyrimidinederivativesasdualinhibitorsofcdk2andtrkakinaseswithantiproliferativeactivity
AT deenaslasheen designsynthesisandmolecularmodelingofpyrazolo15iaipyrimidinederivativesasdualinhibitorsofcdk2andtrkakinaseswithantiproliferativeactivity
AT nerminsamir designsynthesisandmolecularmodelingofpyrazolo15iaipyrimidinederivativesasdualinhibitorsofcdk2andtrkakinaseswithantiproliferativeactivity
AT azzattaher designsynthesisandmolecularmodelingofpyrazolo15iaipyrimidinederivativesasdualinhibitorsofcdk2andtrkakinaseswithantiproliferativeactivity
AT hatemaabdelaziz designsynthesisandmolecularmodelingofpyrazolo15iaipyrimidinederivativesasdualinhibitorsofcdk2andtrkakinaseswithantiproliferativeactivity
AT dalalaabouelella designsynthesisandmolecularmodelingofpyrazolo15iaipyrimidinederivativesasdualinhibitorsofcdk2andtrkakinaseswithantiproliferativeactivity